Practical Recommendations for Community Oncologists Treating RRMM

Physician Summary: Closing Thoughts on the Discussion

Key Takeaway:

• The treatment landscape for relapsed/refractory multiple myeloma (RRMM) is rapidly evolving with advancements in chimeric antigen receptor T-cell (CAR T) therapy, bispecific antibodies, and novel agents. It is essential to tailor treatment strategies based on disease progression, patient comorbidities, and immune fitness.
• Ongoing research and clinical trials will continue to shape our approach, aiming for personalized treatment to improve both efficacy and quality of life.

Looking Ahead:

Patient-centric decision-making remains critical when selecting advanced therapies. As new therapies emerge, sequencing treatments effectively will be vital. The ability to choose the right therapy at the right time can significantly improve outcomes, and discussions like this are essential to optimize patient care.